Arcturus Therapeutics (ARCT) Tops Q4 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Arcturus Therapeutics (ARCT) Tops Q4 EPS by 12c

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

March 1, 2021 4:01 PM EST

ARCT-021 single-shot COVID-19 STARR mRNA vaccine to be advanced to Phase 3 clinical development on track to initiate Phase 3 study in Q2

ARCT-021 single shot immunogenicity profile compares favorably with new data generated from recipients of a single dose of an approved conventional mRNA vaccine

ARCT-810 mRNA therapeutic for ornithine transcarbamylase deficiency to be advanced to Phase 2 clinical development on track to file CTA for Phase 2 multiple dose study in Q2

ARCT-032 mRNA therapeutic for cystic fibrosis: completed successful pre-IND interaction with... More